AltPep Corporation Welcomes Denis Sirringhaus as Vice President of Business Development
13 Agosto 2024 - 7:30AM
Business Wire
AltPep Corporation, a privately held biotechnology company
developing early disease-modifying treatments and detection tools
for amyloid diseases, today announced that Denis Sirringhaus has
joined the company as Vice President of Business Development.
“We are thrilled to welcome Denis to our team,” said Valerie
Daggett, Ph.D., Founder and CEO of AltPep. “Denis’ expertise is
perfectly aligned to drive the partnerships essential for AltPep to
achieve its mission of transforming the treatment and detection of
amyloid diseases, such as Alzheimer’s.”
Denis most recently served as Executive Director of Business
Development at Caribou Biosciences where he helped secure a $25M
Pfizer investment that led to a $100M+ follow-on offering. Prior to
Caribou, Denis worked in Business Development at several biopharma
companies, including Gossamer Bio and Genentech/Roche where he
evaluated neuroscience assets including the in-license of Enspryng®
and the acquisition of Spark Therapeutics. He started his career at
JPMorgan on the Specialty Pharma equity research team. Denis holds
an MBA from Wharton, a Master’s in Biotechnology from the
University of Pennsylvania, and an AB in Biological Sciences from
Harvard.
Denis Sirringhaus expressed his enthusiasm about joining AltPep
stating, “I am excited to be part of the team and look forward to
identifying the best partners for AltPep’s late pre-clinical
program in Alzheimer’s, the SOBA diagnostic based on the same
technology, and other pipeline candidates based on AltPep’s unique
alpha-sheet targeting peptide platform.”
About AltPep Corporation AltPep is developing
groundbreaking disease-modifying treatments and detection tools for
amyloid diseases by targeting early molecular triggers: toxic
soluble oligomers. Our customized, synthetic peptides are designed
to bind selectively to toxic oligomers to both detect and
neutralize them throughout disease progression. AltPep’s emphasis
is on early, pre-symptomatic detection and treatment. Our lead
programs focus on Alzheimer’s and Parkinson’s diseases, with other
amyloid diseases, such as Type 2 diabetes, on the horizon. AltPep’s
goal is to change the course of these debilitating diseases that
affect over a billion people around the globe.
Decades of scientific research by the Daggett Research Group at
the UW provided the foundation for AltPep’s innovative
approach.
For more information, please visit altpep.com and follow us on
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240813742719/en/
Media: Susan Sharpe Linnden Communications
susan@linndencom.com